	US 12,110,502 B2
	Models of tauopathy
Marine Prissette, Brooklyn, NY (US); Matthew Koss, Pleasantville, NY (US); Mathieu Desclaux, Brooklyn, NY (US); John McWhirter, Hastings-on-Hudson, NY (US); Arijit Bhowmick, Astoria, NY (US); David Frendewey, New York, NY (US); Brian Zambrowicz, Sleepy Hollow, NY (US); and Claudia Racioppi, New York, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Nov. 6, 2023, as Appl. No. 18/502,516.
Application 18/502,516 is a division of application No. 16/900,432, filed on Jun. 12, 2020, granted, now 11,845,957.
Claims priority of provisional application 62/861,553, filed on Jun. 14, 2019.
Prior Publication US 2024/0076613 A1, Mar. 7, 2024
Int. Cl. C12N 15/113 (2010.01); A61K 9/00 (2006.01); A61K 48/00 (2006.01); C12N 5/0793 (2010.01); C12Q 1/68 (2018.01); C07H 21/02 (2006.01)

CPC C12N 5/0619 (2013.01) [A61K 9/0019 (2013.01); A61K 48/0058 (2013.01); C12N 15/113 (2013.01); A01K 2267/0312 (2013.01); A01K 2267/0318 (2013.01); C12N 2310/11 (2013.01)]

42 Claims

1. A non-human animal comprising:

(a) a microtubule-associated protein tau coding sequence in one or more cells; and

(b) (i) a genetic modification in one or more or all of BANF1, PPP2CA, and ANKLE2 that reduces expression of the one or more or all of BANF1, PPP2CA, and ANKLE2, respectively, in the one or more cells and/or (ii) one or more agents that reduce expression of one or more or all of BANF1, PPP2CA, and ANKLE2 in the one or more cells,

wherein the microtubule-associated protein tau coding sequence is an exogenous human microtubule-associated protein tau coding sequence and/or wherein the microtubule-associated protein tau comprises a tauopathy-associated mutation.